ABSTRACT:
The introduction of prostate specific membrane antigen (PSMA)-positron emission tomography (PET) using 68 Ga revolutionized prostate cancer imaging. Outperforming standard imaging, it allows complete staging of the local tumor and possible lymph nodes, visceral or bone metastases with high accuracy in only one examination (1,2).
Sensitivities of 66% and specificities of 99% were observed for primary lymph node staging (2) . Moreover, it has become an excellent staging tool for recurrent prostate cancer even at early stage and low PSA levels (1,3). PSMA-positive detection rates of 50%-58% were reported for serum PSA values less than <0.5 ng/mL, 58%-73% for PSA values of 0.5-<1ng/mL and up to >90% at higher PSA values (1,3). Considering the high incidence of prostate cancer worldwide, the possibility of large scale batch production capacity of the novel By now several radiolabelled small-molecule inhibitors of PSMA have been designed (8) . Currently, the low-molecular weight PSMA inhibitor 68 Ga-PSMA-11 is the most widely used PET tracer (9), but might have some disadvantages with respect to production capacity and nuclear decay properties. Anyhow, its main advantage is the commercial availability of gallium-68 ( Ga-PSMA-617 is remarkable higher (>10% ID over 2h) (1, 16, 19) . However, this improvement is less related to the radiolabelling moiety but rather to the optimized structure of the overall molecule. (Figure-1 ). Today it is rather the perspective of "decentralized" or "centralized" production to achieve adequate coverage for the clinical demand of examination capacity.
